| Institution: | 1. German Centre for Infection Research, Tübingen University Hospital, Tübingen, Germany;2. Verona University Hospital, Verona, Italy;3. World Health Organization Collaborating Centre on Patient Safety, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland;4. Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa;5. European Centre for Disease Prevention and Control, Stockholm, Sweden;6. EA 4360 APEMAC, Nancy University Hospital, Lorraine University, Nancy, France;7. Central Hospital, Växjö, Sweden;8. University Medical Center, Utrecht, Netherlands;9. Amphia Hospital, Breda, Netherlands;10. Laboratory for Microbiology and Infection Control, Tel Aviv University, Tel Aviv, Israel;11. Laval University and Canadian Institutes for Health Research, Québec, QC, Canada;12. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator CARB-X, Boston University, Boston, MA, USA;13. Centers for Disease Control and Prevention, Atlanta, GA, USA;14. European Medicines Agency, London, UK;15. US Food and Drug Administration, Washington, DC, USA;p. Antibacterials Program Biomedical Advanced Research and Development Authority, Washington, DC, USA;q. Austin Health, University of Melbourne, Melbourne, VIC, Australia;r. Department of Infectious Diseases and Microbiology, University of Otago, Dunedin, New Zealand;s. Children''s National Health System, George Washington University, Washington, DC, USA;t. Center for Anti-infective Agents, Vienna, Austria;u. Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland |
